Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Aschaffenburg – page 44

1 096 clinical trials in Aschaffenburg, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Aschaffenburg at a glance
1 096
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 096 trials in Aschaffenburg

Open in trial search

Psoriasis

Not recruiting

ORKA-001 in Patients with Moderate-to-Severe Plaque Psoriasis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ORKA-001
  • Sponsor:Oruka Therapeutics Inc.

Obesity

Not recruiting

RO7795068 for Weight Loss in Adults With Obesity or Overweight Without Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Enicepatide
  • Sponsor:F. Hoffmann-La Roche AG

Rheumatoid arthritis

Not recruiting

Baricitinib Compared with Adalimumab and Etanercept in Patients with Rheumatoid Arthritis

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Eli Lilly & Co.

Obesity

Not recruiting

Efficacy and Safety of MET097 Once Weekly in People with Overweight or Obesity and Type 2 Diabetes

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide
  • Sponsor:Metsera Inc.

Obesity

Not recruiting

A study to evaluate the efficacy and safety of MET097 in people with obesity or overweight.

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Berobenatide
  • Sponsor:Metsera Inc.

Dermatitis atopic

Not recruiting

A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Galvokimig
  • Sponsor:UCB Biopharma

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Olpasiran
  • Sponsor:Amgen Inc.

Study of Trontinemab Compared to Placebo for Patients with Early Symptomatic Alzheimer's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetapir (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing trontinemab compared to placebo in patients with early Alzheimer's disease including mild cognitive impairment and mild dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Florbetapir (18F)
  • Sponsor:F. Hoffmann-La Roche AG

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Dermatitis atopic

Not recruiting

A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:KT-621
  • Sponsor:Kymera Therapeutics Inc.

Other cities in Germany

The busiest research cities in the country

All 503 cities in Germany

Clinical research in Aschaffenburg

What the registry says about research in the country

01 Hematologic Oncology

Groundbreaking research focusing on acute myeloid leukemia and chronic lymphocytic leukemia, evaluating novel therapeutic approaches including targeted therapies and combination treatments. Studies examine innovative drug combinations to improve patient outcomes in various blood cancers.

  • FLT3-mutation targeted therapies
  • Chemotherapy optimization
  • Novel drug combinations

Multiple trials investigating treatments for both newly diagnosed and relapsed/refractory patients.

02 Breast Cancer Research

Advanced studies in hormone receptor-positive breast cancer, particularly focusing on metastatic disease. Investigations include new combination therapies and targeted treatments for patients with specific genetic mutations.

  • ESR1-mutation treatments
  • CDK4/6 inhibitor combinations
  • Endocrine therapy resistance

Research emphasizes personalized treatment approaches based on molecular profiles.

03 Respiratory Medicine

Innovative research in severe asthma treatment, particularly focusing on patients with eosinophilic phenotype. Studies evaluate new biological therapies and compare their efficacy with existing treatments.

  • Anti-IL-5/5R therapy
  • Long-term efficacy studies
  • Phenotype-specific treatments

Trials aim to improve long-term management of severe respiratory conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.